Skip to main content Help with accessibility Skip to main navigation

April 2021 updates to the website

The website has now been updated following April's LSCMMG

The following Items have been updated and added to the website and will be ratified following the next Joint Committee of CCGs (JCCCG) Meeting:

Erenumab - For preventing migraine (TA682)

Baricitinib - For treating moderate to severe atopic dermatitis (TA681)